{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-202285","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.115826+00:00","generated_at":"2026-06-12T08:54:31.275579+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AlloVir Q2 net loss $45.3M; cash $246.5M; three Phase 3 trials on track for H2 2024 data","bullets":["Net loss of $45.3M ($0.48 per share) vs $44.6M ($0.69) in Q2 2022.","Cash, equivalents, and short-term investments $246.5M as of June 30, 2023.","Closed public offering with gross proceeds ~$75M, extending cash runway into 2025.","Three Phase 3 registrational trials of posoleucel in allo-HCT patients; data expected H2 2024.","FY 2023 operating expense guidance $150M-$170M excluding non-cash items."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-202285","json":"https://secwatch.observer/filing/0001193125-23-202285.json","markdown":"https://secwatch.observer/filing/0001193125-23-202285.md","text":"https://secwatch.observer/filing/0001193125-23-202285.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312523202285/0001193125-23-202285-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312523202285/d533010d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T08:54:31.275579+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"768f139dfca24ea9a8d017c6eb3425b28a647ae9","claim":"Kalaris Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income net loss was $45.3 million or $0.48 per share, EPS $0.48 per share. Guidance reaffirmed.","evidence_excerpt":"For the quarter ended June 30, 2023, net loss was $45.3 million or $0.48 per share compared with a net loss of $44.6 million or $0.69 per share for the quarter ended June 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312523202285/0001193125-23-202285-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Net income","value":"net loss was $45.3 million or $0.48 per share"},{"label":"EPS","value":"$0.48 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}